We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$346M
AUM Growth
+$66.9M
Cap. Flow
+$19.7M
Cap. Flow %
5.7%
Top 10 Hldgs %
98.75%
Holding
15
New
1
Increased
6
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$9.52M
2
TCRX icon
TScan Therapeutics
TCRX
+$3.61M
3
GHRS icon
GH Research
GHRS
+$3.32M
4
DTIL icon
Precision BioSciences
DTIL
+$1.33M
5
STOK icon
Stoke Therapeutics
STOK
+$1.07M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$82.5M 23.84%
1,568,841
– –
GHRS icon
2
GH Research
GHRS
$1.93B
$82.2M 23.76%
6,746,951
+303,011
+5% +$3.32M
STOK icon
3
Stoke Therapeutics
STOK
$1.8B
$61.3M 17.72%
5,404,674
+112,745
+2% +$1.07M
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.79B
$40.5M 11.7%
733,014
– –
CGEM icon
5
Cullinan Oncology
CGEM
$1.01B
$33.1M 9.57%
4,400,842
+1,185,120
+37% +$9.52M
ALLO icon
6
Allogene Therapeutics
ALLO
$649M
$12.5M 3.61%
11,057,009
– –
TCRX icon
7
TScan Therapeutics
TCRX
$48.6M
$11.4M 3.29%
7,857,347
+2,500,000
+47% +$3.61M
CCCC icon
8
C4 Therapeutics
CCCC
$385M
$10.2M 2.93%
7,098,133
– –
DTIL icon
9
Precision BioSciences
DTIL
$180M
$4.35M 1.26%
1,036,051
+270,000
+35% +$1.33M
PASG icon
10
Passage Bio
PASG
$14.4M
$3.71M 1.07%
462,848
– –
UPB
11
Upstream Bio Inc
UPB
$343M
$2.41M 0.7%
219,247
– –
IBIO icon
12
iBio
IBIO
$69.5M
$1.17M 0.34%
1,538,573
+676,294
+78% +$734K
NEUP
13
Neuphoria Therapeutics
NEUP
$21M
$325K 0.09%
45,806
– –
DSGN icon
14
Design Therapeutics
DSGN
$761M
$222K 0.06%
65,954
– –
ASMB icon
15
Assembly Biosciences
ASMB
$498M
$188K 0.05%
+10,366
New +$137K

Similar funds

RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
SIC
SFE Investment Counsel Los Angeles, California $635M AUM 23.85% 1-Year Est. Return

Lynx1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Lynx1 Capital Management held 15 positions worth $346M, up 24% from $279M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Lynx1 Capital Management deployed $19.7M of net new capital in Q2 2025, opening 1 new position and adding to 6 existing holdings. Its largest new stake was Assembly Biosciences: 10,366 shares worth $188K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management's largest Q2 2025 buy was Assembly Biosciences: 10,366 shares worth $188K.
  • Lynx1 Capital Management added most to Cullinan Oncology in Q2 2025, an estimated $9.52M increase.
  • Lynx1 Capital Management's ten largest holdings make up 99% of its $346M portfolio in Q2 2025.
  • Lynx1 Capital Management opened 1 new position and closed 0 in Q2 2025.
  • Lynx1 Capital Management's portfolio value rose 24% quarter-over-quarter to $346M.

Based on Lynx1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.